Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic LeukemiaValentina Griggio, Marta Coscia, Candida Vitale et al.|Blood|2024Cited by 1
Prevalence and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Chronic Lymphocytic Leukemia and Richter TransformationChiara Cosentino, Riccardo Moia, Annalisa Gaglio et al.|Blood|2024Cited by 1
CLL-1206: Prevalence and Clinical Impact of Clonal Hematopoiesis in Chronic Lymphocytic LeukemiaSamir Mouhssine, Riccardo Moia, Chiara Cosentino et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
POSTER: CLL-1206 Prevalence and Clinical Impact of Clonal Hematopoiesis in Chronic Lymphocytic LeukemiaSamir Mouhssine, Riccardo Moia, Chiara Cosentino et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
Venetoclax-based therapy remodels T-cell and NK-cell immunity in patients with chronic lymphocytic leukemiaGiorgia Mancin, Marta Coscia, Valentina Griggio et al.|Blood|2025Cited by 0